Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAMEL study of cabozantinib monotherapy in pediatric recurrent or refractory solid tumors
jRCT2031210610Completed
- Sponsor
- Takeda
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cabozantinib in Non-hematologic malignancy and pediatric solid tumors, sponsored by Takeda. Primary endpoint: Incidence of DLT-equivalent toxicities. Started Apr 2022; status: completed.
02
Drugs
cabozantinib
03
Conditions
Non-hematologic malignancypediatric solid tumors
Beyond the preview
Go deeper on jRCT2031210610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210610.